… financial results for its first quarter of fiscal year 2026, … amp;A for the first quarter ended September 30, 2025 … operating expenses and capital expenditure into the fourth quarter … InMed: InMed Pharmaceuticals is a pharmaceutical drug development company …

… November 7, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations … target specialties. In the first quarter, we expanded our portfolio … reconciliation to our GAAP expenditures. Non-GAAP cost of … Disease team in the first quarter. Adjusted non-GAAP diluted …

… business or making capital expenditure investments. Healthcare companies … meet expectations in the first quarter, and the company acknowledged … processed 475.6 million pharmacy claims, and served 26 … business units. Period Pharmacy and Consumer Wellness Health …

… wholly owned subsidiary, Zydus Pharmaceuticals (USA) Inc., has launched … in partnership with Carnegie Pharmaceuticals LLC. Biocon has … 2 diabetes mellitus). Regarding Q1 FY26 financials, the … affect margins. High capital expenditure and long gestation periods …

… marking NeuroPace's first quarter of positive adjusted EBITDA, … revenue by quarter, from Q1 2024 through today… operating cash flow less capital expenditures, was negative $2 … can support some of these pharma collaborations. Mike Kratky: Understood …

… growth in biologics, rising pharmaceutical innovation, and the increasing … third quarter of 2025, capital expenditures totaled $54.9 million. … So this was translated in Q1, Q2, and Q3 in … as a percentage from that first quarter favorable level was somewhat …

… current operations into the first quarter of 2027. With that … are anticipated for the first quarter of 2026. As we … certepetide’s chemical structures, pharmacokinetic properties, methods of manufacturing … includes in terms of expenditures going into 2026? David …

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in …

… to go live in the first quarter of 2026, though a number … our ability to maintain our pharmacy distribution network if there is … ; our relationship with key pharmacy program partners or any decline … does not reflect these capital expenditures; (3) it does not …

… the first quarter of next year. However, we still expect Q1 to … our financial reorganization. Capital expenditures in Q3 totaled $3 … calendar days of the first quarter. Now shifting to our … industry from regulators to pharma partners will increasingly value …